Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke: A Canadian Healthcare Perspective

Author： Sinclair S.E.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.9, 2001-01, pp. : 927-936

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 2, 2013-04 ,pp. : 155-169

Bentham Science Publishers

Access to resources Recommend Favorite

Discounting in Cost-Utility Analysis of Healthcare Interventions: Reassessing Current Practice

By Cohen B.J.  

PharmacoEconomics, Vol. 21, Iss. 2, 2003-01 ,pp. : 75-87

Adis International

Access to resources Recommend Favorite

Tissue-type plasminogen activator as a therapeutic target in stroke

By Gravanis Iordanis   Tsirka Stella E  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 2, 2008-02 ,pp. : 159-170

Informa Healthcare

Access to resources Recommend Favorite

Alteplase cost-effective option for acute ischaemic stroke

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 333, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

By  

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3677-3684

Bentham Science Publishers

Access to resources Recommend Favorite